{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:57:57Z","timestamp":1784782677609,"version":"3.55.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The objective of this study was to investigate timing and risk factors for discontinuation of short-course tuberculosis preventive therapy (TPT) comparing directly observed 3-month isoniazid\/rifapentine (3HP) vs self-administered 4-month rifampin (4R).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a subanalysis of a 6-month health department cohort (2016\u20132017) of 993 latent tuberculosis infection (LTBI) patients initiating 3HP (20%) or 4R (80%). Time at risk of TPT discontinuation was compared across regimens. Risk factors were assessed using mixed-effects Cox models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Short-course TPT discontinuation was higher with 4R (31% vs 14%; P &amp;lt; .0001), though discontinuation timing was similar. Latino ethnicity (hazard ratio [HR], 1.80; 95% CI, 1.20\u20132.90) and adverse events (HR, 4.30; 95% CI, 2.60\u20137.30) increased 3HP discontinuation risk. Social\u2013behavioral factors such as substance misuse (HR, 12.00; 95% CI, 2.20\u201369.00) and congregate living (HR, 21.00; 95% CI, 1.20\u2013360.00) increased 4R discontinuation risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TPT discontinuation differed by regimen, with distinct risk factors. Addressing social determinants of health within TPT programs is critical to enhance completion rates and reduce TB disease risk in marginalized populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae313","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:42:26Z","timestamp":1717677746000},"source":"Crossref","is-referenced-by-count":2,"title":["Factors Associated With the Discontinuation of Two Short-Course Tuberculosis Preventive Therapies in Programmatic Settings in the United States"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2409-2061","authenticated-orcid":false,"given":"Michael","family":"Asare-Baah","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Florida , Gainsville, Florida , USA"},{"name":"Emerging Pathogens Institute, University of Florida , Gainsville, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaTweika A T","family":"Salmon-Trejo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases and Global Medicine, University of Florida , Gainsville, Florida , USA"},{"name":"Institute of Public Health, Florida A & M University , Tallahassee, Florida , USA"},{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thara","family":"Venkatappa","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S","family":"Garfein","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health, University of California , San Diego, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylynn","family":"Aiona","sequence":"additional","affiliation":[{"name":"Public Health Institute at Denver Health , Denver, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Haas","sequence":"additional","affiliation":[{"name":"Division of Mycobacterial and Respiratory Infections, National Jewish Health , Denver, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Nancy","family":"S\u00e9raphin","sequence":"additional","affiliation":[{"name":"Emerging Pathogens Institute, University of Florida , Gainsville, Florida , USA"},{"name":"Department of Medicine, Division of Infectious Diseases and Global Medicine, University of Florida , Gainsville, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2024062411253340200_ofae313-B1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.5588\/ijtld.18.0757","article-title":"Changes in tuberculosis epidemiology, United States, 1993\u20132017","volume":"23","author":"Armstrong","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062411253340200_ofae313-B2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.15585\/mmwr.mm7212a1","article-title":"Tuberculosis\u2014United States, 2022","volume":"72","author":"Schildknecht","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024062411253340200_ofae313-B3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jiy265","article-title":"Risk and timing of tuberculosis among close contacts of persons with infectious tuberculosis","volume":"218","author":"Reichler","year":"2018","journal-title":"J Infect Dis"},{"key":"2024062411253340200_ofae313-B4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201508-1683OC","article-title":"The prevalence of latent tuberculosis infection in the United States","volume":"194","author":"Mancuso","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024062411253340200_ofae313-B5","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011\u20132012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"key":"2024062411253340200_ofae313-B6","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"2024062411253340200_ofae313-B7","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024062411253340200_ofae313-B8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","article-title":"Improved treatment completion with shorter treatment regimens for latent tuberculous infection","volume":"22","author":"Macaraig","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062411253340200_ofae313-B9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1_Suppl","key":"2024062411253340200_ofae313-B10","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1177\/0033354919826557","article-title":"Completion rates, adverse effects, and costs of a 3-month and 9-month treatment regimen for latent tuberculosis infection in California inmates, 2011\u20132014","volume":"134","author":"Wheeler","year":"2019","journal-title":"Public Health Rep"},{"key":"2024062411253340200_ofae313-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2024062411253340200_ofae313-B12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-0038-1660863","article-title":"Updates in the treatment of active and latent tuberculosis","volume":"39","author":"Haas","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2024062411253340200_ofae313-B13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024062411253340200_ofae313-B14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1060028019888855","article-title":"Evaluation of 3 months of once-weekly rifapentine and isoniazid for latent tuberculosis infection","volume":"54","author":"Walker","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2024062411253340200_ofae313-B15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2024062411253340200_ofae313-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-019-7524-4","article-title":"Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis","volume":"19","author":"S\u00e9raphin","year":"2019","journal-title":"BMC Public Health"},{"key":"2024062411253340200_ofae313-B17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5588\/ijtld.14.0373","article-title":"Latent tuberculous infection in the United States and Canada: who completes treatment and why?","volume":"19","author":"Hirsch-Moverman","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062411253340200_ofae313-B18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/cid\/ciw126","article-title":"Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB trial in the United States and Canada","volume":"62","author":"Moro","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024062411253340200_ofae313-B19","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/cid\/ciac248","article-title":"Evaluation of the latent tuberculosis care cascade among public health clinics in the United States","volume":"75","author":"Holzman","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024062411253340200_ofae313-B20","doi-asserted-by":"crossref","first-page":"E3459","DOI":"10.1093\/cid\/ciaa1364","article-title":"Higher completion rates with self-administered once-weekly isoniazid-rifapentine versus daily rifampin in adults with latent tuberculosis","volume":"73","author":"Haas","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024062411253340200_ofae313-B21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.0006-341X.2000.01016.x","article-title":"Estimation of multivariate frailty models using penalized partial likelihood","volume":"56","author":"Ripatti","year":"2000","journal-title":"Biometrics"},{"key":"2024062411253340200_ofae313-B22","doi-asserted-by":"crossref","first-page":"e0241124","DOI":"10.1371\/journal.pone.0241124","article-title":"Patient-perceived treatment burden of tuberculosis treatment","volume":"15","author":"Ting","year":"2020","journal-title":"PLoS One"},{"key":"2024062411253340200_ofae313-B23","doi-asserted-by":"crossref","first-page":"e0246113","DOI":"10.1371\/journal.pone.0246113","article-title":"Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda","volume":"16","author":"Lim","year":"2021","journal-title":"PLoS One"},{"key":"2024062411253340200_ofae313-B24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1086\/594126","article-title":"Tuberculosis and illicit drug use: review and update","volume":"48","author":"Deiss","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024062411253340200_ofae313-B25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/09540121.2013.804900","article-title":"The effect of history of injection drug use and alcoholism on HIV disease progression","volume":"26","author":"Lima","year":"2014","journal-title":"AIDS Care"},{"key":"2024062411253340200_ofae313-B26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/NNR.0000000000000545","article-title":"Effect of a nurse-led community health worker intervention on latent tuberculosis medication completion among homeless adults","volume":"70","author":"Nyamathi","year":"2021","journal-title":"Nurs Res"},{"key":"2024062411253340200_ofae313-B27","first-page":"1104","article-title":"Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience","volume":"14","author":"Hirsch-Moverman","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024062411253340200_ofae313-B28","doi-asserted-by":"crossref","first-page":"e058751","DOI":"10.1136\/bmjopen-2021-058751","article-title":"Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study","volume":"12","author":"Runels","year":"2022","journal-title":"BMJ Open"},{"key":"2024062411253340200_ofae313-B29","doi-asserted-by":"crossref","first-page":"e0000017","DOI":"10.1371\/journal.pgph.0000017","article-title":"Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: a qualitative descriptive study","volume":"1","author":"Heyd","year":"2021","journal-title":"PLOS Glob Public Heal"},{"key":"2024062411253340200_ofae313-B30","article-title":"12-dose isoniazid (INH)\/rifapentine regimen for treatment of latent TB infection (LTBI)","author":"Authority"},{"key":"2024062411253340200_ofae313-B31","article-title":"Rifampin for latent TB infection (LTBI) treatment","author":"Tuberculosis","year":"2018"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae313\/58137997\/ofae313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae313\/58311800\/ofae313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae313\/58311800\/ofae313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T11:44:03Z","timestamp":1719229443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae313\/7688857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae313","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,6]]},"article-number":"ofae313"}}